HRP20170325T1 - Farmaceutska doza koja sadrži farmaceutski prihvatljivu otapajuću smjesu - Google Patents
Farmaceutska doza koja sadrži farmaceutski prihvatljivu otapajuću smjesu Download PDFInfo
- Publication number
- HRP20170325T1 HRP20170325T1 HRP20170325TT HRP20170325T HRP20170325T1 HR P20170325 T1 HRP20170325 T1 HR P20170325T1 HR P20170325T T HRP20170325T T HR P20170325TT HR P20170325 T HRP20170325 T HR P20170325T HR P20170325 T1 HRP20170325 T1 HR P20170325T1
- Authority
- HR
- Croatia
- Prior art keywords
- mixture
- amino
- pharmaceutically acceptable
- dose
- melt
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 5
- 239000002552 dosage form Substances 0.000 title 1
- 230000003381 solubilizing effect Effects 0.000 title 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 11
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 5
- 239000004480 active ingredient Substances 0.000 claims 5
- 229920001577 copolymer Polymers 0.000 claims 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims 4
- 239000000194 fatty acid Substances 0.000 claims 4
- 229930195729 fatty acid Natural products 0.000 claims 4
- 150000004665 fatty acids Chemical class 0.000 claims 4
- 229920001519 homopolymer Polymers 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000007787 solid Substances 0.000 claims 4
- 239000007962 solid dispersion Substances 0.000 claims 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 3
- 239000004030 hiv protease inhibitor Substances 0.000 claims 3
- 239000004615 ingredient Substances 0.000 claims 3
- 239000012803 melt mixture Substances 0.000 claims 3
- 229930003799 tocopherol Natural products 0.000 claims 3
- 235000010384 tocopherol Nutrition 0.000 claims 3
- 239000011732 tocopherol Substances 0.000 claims 3
- 229960001295 tocopherol Drugs 0.000 claims 3
- 229940122440 HIV protease inhibitor Drugs 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000000155 melt Substances 0.000 claims 2
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 229940087168 alpha tocopherol Drugs 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000006835 compression Effects 0.000 claims 1
- 238000007906 compression Methods 0.000 claims 1
- 150000005690 diesters Chemical class 0.000 claims 1
- 239000006260 foam Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 229960004525 lopinavir Drugs 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- -1 propylene glycol ester Chemical class 0.000 claims 1
- 229940026235 propylene glycol monolaurate Drugs 0.000 claims 1
- 229960000311 ritonavir Drugs 0.000 claims 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 1
- 239000011877 solvent mixture Substances 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 229960000984 tocofersolan Drugs 0.000 claims 1
- 235000004835 α-tocopherol Nutrition 0.000 claims 1
- 239000002076 α-tocopherol Substances 0.000 claims 1
- 125000001020 α-tocopherol group Chemical group 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (13)
1. Farmaceutska doza koja sadrži smjesu taline od barem jednog aktivnog sastojka, barem jednog farmaceutski prihvatljivog homopolimera ili kopolimera N-vinilpirolidona i otapajuća smjesa, pri čemu je aktivni sastojak prisutan kao čvrsta disperzija, a otapajuća smjesa sadrži (i) barem jedan tokoferol sastojak koji odgovara formuli (I)
[image]
(I)
naznačen time da je
Z ostatak alifatične dvobazne kiseline,
R1 i R2 su, neovisno jedan o drugome, hidrogen ili C1-C4 alkil i
n je cijeli broj od 5 do 100,
i (ii) barem jedan propilen glikol monoester masne kiseline ili smjesu propilen glikol mono- ili diester masne kiseline, naznačen time da doza sadrži, u odnosu na masu smjese taline, od otprilike 0,5 do 40 % mase aktivnog sastojka, 40 do 90 % mase farmaceutski prihvatljivog homopolimera ili kopolimera N-vinilpirolidona, 0,5 do 20 % mase otapajuće smjese, i 0 do 15 % mase aditiva.
2. Doza temeljem zahtjeva 1, naznačena time da je tokoferol sastojak alfa tokoferol polietilen glikol sukcinat.
3. Doza temeljem zahtjeva 1 ili 2, naznačena time da je propilen glikol monoester masne kiseline propilen glikol monolaurat.
4. Doza temeljem bilo kojeg od prethodnih zahtjeva, naznačena time da je omjer mase tokoferol sastojka i propilen glikol estera masne kiseline između 9:1 i 1:9.
5. Doza temeljem bilo kojeg od prethodnih zahtjeva, naznačena time da je aktivni sastojak inhibitor proteaze HIV-a ili kombinacija inhibitora proteaze HIV-a.
6. Doza temeljem zahtjeva 5, naznačena time da je predmetni inhbitor proteaze HIV-a izabran iz skupine koja obuhvaća: 2S, 3S, 5S)-5-(N-(N-((N-metil-N-((2-izopropil-4-tiazolil)metil)amino)karbonil)-L-valinil)amino-2-(N-((5-tiazolil)metoksi-karbonil)-amino)-amino-1,6-difenil-3-hidriksiheksan (ritonavir); (2S,3S,5S)-2-(2,6-Dimetilfenoksiacetil)amino-3-hidroksi-5-[2S-(I-tetrahidro-pirimid-2-onil)-3-metilbutanoil]amino-1,6-difenilheksan (lopinavir); ili njihova kombinacija.
7. Kruta doza temeljem bilo kojeg od prethodnih zahtjeva, naznačena time da je farmacuetski prihvatljiv homopolimer ili kopolimer N-vinilpirolidona kopolimer N-vinil pirolidona i vinil acetata.
8. Kruta doza temeljem bilo kojeg od prethodnih zahtjeva, naznačena time da je barem jedan aditiv izabran između regulatora protoka, sredstava za dezintegriranje, agensa za rahljenje i maziva.
9. Kruta doza temeljem bilo kojeg od prethodnih zahtjeva, naznačen time da smjesa taline ima Tg 10 °C ili više.
10. Postupak pripreme krute doze temeljem zahtjeva 1, naznačen time da obuhvaća:
A. pripremu homogene taline aktivno/ih sastojka/aka farmaceutski prihvatljivog homopolimera ili kopolimera N-vinilpirolidona i otapajuće smjese, i
B. puštanje da talina očvrsne radi dobivanja čvrstog disperzijskog proizvoda.
11. Postupak temeljem zahtjeva 10, naznačen time da dodatno obuhvaća mljevenje čvrstog disperzijskog proizvoda i njegovu kompresiju u tabletu.
12. Postupak temeljem zahtjeva 10, naznačen time da dodatno obuhvaća mljevenje čvrstog disperzijskog proizvoda i njegovo punjenje u oklop kapsule.
13. Postupak temeljem zahtjeva 10, naznačen time da je talina u obliku filma ili pjene prije nego se pusti da očvrsne.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83207406P | 2006-07-19 | 2006-07-19 | |
EP06015076A EP1880715A1 (en) | 2006-07-19 | 2006-07-19 | Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same |
PCT/EP2007/057392 WO2008009689A1 (en) | 2006-07-19 | 2007-07-17 | Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same |
EP07787658.9A EP2046298B1 (en) | 2006-07-19 | 2007-07-17 | Pharmaceutical dosage form containing pharmaceutically acceptable solubilizing composition |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20170325T1 true HRP20170325T1 (hr) | 2017-04-21 |
Family
ID=37496705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20170325TT HRP20170325T1 (hr) | 2006-07-19 | 2017-02-28 | Farmaceutska doza koja sadrži farmaceutski prihvatljivu otapajuću smjesu |
Country Status (22)
Country | Link |
---|---|
US (2) | US9078921B2 (hr) |
EP (2) | EP1880715A1 (hr) |
JP (1) | JP5244102B2 (hr) |
KR (1) | KR101424588B1 (hr) |
CN (2) | CN101489537B (hr) |
AU (1) | AU2007275177B2 (hr) |
BR (1) | BRPI0715582A2 (hr) |
CA (1) | CA2658395C (hr) |
CY (1) | CY1118873T1 (hr) |
DK (1) | DK2046298T3 (hr) |
ES (1) | ES2612865T3 (hr) |
HR (1) | HRP20170325T1 (hr) |
HU (1) | HUE032551T2 (hr) |
LT (1) | LT2046298T (hr) |
MX (1) | MX2009000048A (hr) |
PL (1) | PL2046298T3 (hr) |
PT (1) | PT2046298T (hr) |
RS (1) | RS55705B1 (hr) |
RU (1) | RU2469708C2 (hr) |
SI (1) | SI2046298T1 (hr) |
WO (1) | WO2008009689A1 (hr) |
ZA (1) | ZA200901110B (hr) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5222550B2 (ja) * | 2007-12-27 | 2013-06-26 | 財團法人工業技術研究院 | 徐放性組成物およびその製造方法 |
US9161943B2 (en) | 2007-12-31 | 2015-10-20 | Industrial Technology Research Institute | Sustained release composition and manufacturing method thereof |
US8728516B2 (en) | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
WO2010137027A1 (en) * | 2009-05-27 | 2010-12-02 | Hetero Research Foundation | Solid oral dosage forms of lamivudine |
TWI540132B (zh) * | 2009-06-08 | 2016-07-01 | 亞培公司 | Bcl-2族群抑制劑之口服醫藥劑型 |
US20110034489A1 (en) * | 2009-07-31 | 2011-02-10 | Ranbaxy Laboratories Limited | Solid dosage forms of hiv protease inhibitors |
CA2780177A1 (en) | 2009-12-22 | 2011-06-30 | Abbott Laboratories | Abt-263 capsule |
NZ602288A (en) * | 2010-03-10 | 2014-02-28 | Abbvie Bahamas Ltd | Solid compositions comprising amorphous (2r,6s,13as,14ar,16as,z)-n-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide |
CA2811805A1 (en) | 2010-10-29 | 2012-05-03 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
KR101923364B1 (ko) | 2010-11-23 | 2018-11-30 | 애브비 인코포레이티드 | 아폽토시스유도제의 염 및 결정형 |
DK2642999T3 (en) | 2010-11-23 | 2017-01-09 | Abbvie Ireland Unlimited Co | METHODS OF TREATMENT FOR USING selectivity-VE BCL-2 INHIBITORS |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
BR112014012444B1 (pt) | 2011-11-23 | 2021-12-14 | Therapeuticsmd, Inc | Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130172375A1 (en) * | 2011-12-13 | 2013-07-04 | Hoffmann-La Roche Inc. | Pharmaceutical composition |
US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
CN104661652B (zh) * | 2012-09-27 | 2018-08-28 | 巴斯夫欧洲公司 | 包含至少一种水溶性维生素e衍生物和至少一种亲水聚合物的储存稳定的无粉尘均质颗粒状配制剂 |
US9789063B2 (en) | 2012-09-27 | 2017-10-17 | Basf Se | Storage-stable dust-free homogeneous particulate formulation |
US9744240B2 (en) | 2012-09-27 | 2017-08-29 | Basf Se | Storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin E-derivative and at least one hydrophilic polymer |
EP2911651B1 (en) * | 2012-09-27 | 2016-06-22 | Basf Se | A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer |
KR102191562B1 (ko) * | 2012-11-07 | 2020-12-15 | 에스케이바이오팜 주식회사 | 난용성 약물의 고체분산체 및 이의 제조방법 |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
JP2017516768A (ja) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 天然の併用ホルモン補充療法剤及び療法 |
CN106456556A (zh) * | 2014-06-18 | 2017-02-22 | 豪夫迈·罗氏有限公司 | 包含非离子性表面活性剂的新型药物组合物 |
CN104523615B (zh) * | 2014-12-12 | 2017-07-04 | 常州康普药业有限公司 | 一种舒必利片及其制备方法 |
CN104784179A (zh) * | 2015-04-01 | 2015-07-22 | 重庆理工大学 | 替拉那韦在抗乳腺癌药物中的应用及抗乳腺癌药物 |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
EP3435977A4 (en) | 2016-04-01 | 2019-10-16 | Therapeuticsmd, Inc. | PHARMACEUTICAL COMPOSITION OF STEROID HORMONE |
RU2619840C1 (ru) * | 2016-09-21 | 2017-05-18 | Общество с ограниченной ответственностью "Изварино Фарма" | Фармацевтическая композиция для лечения ВИЧ-инфекции |
RU2659693C1 (ru) * | 2017-06-30 | 2018-07-03 | Общество с ограниченной ответственностью "Изварино Фарма" | Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции |
CA3105187A1 (en) | 2018-06-28 | 2020-01-02 | Arx, Llc | Dispensing method for producing dissolvable unit dose film constructs |
KR102114550B1 (ko) * | 2018-07-10 | 2020-05-22 | 삼육대학교산학협력단 | 생리학적 체내 동태 연구 모델링을 이용한 약제학적 조성물의 제조 방법 |
CN111821309B (zh) * | 2020-04-30 | 2021-08-24 | 深圳市新阳唯康科技有限公司 | 一种具有改良溶出速度的达芦那韦组合物 |
CN117338733B (zh) * | 2023-10-12 | 2024-05-28 | 杭州和泽坤元药业有限公司 | 一种富马酸替诺福韦二吡呋酯片及其制备工艺 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY126358A (en) * | 1996-03-22 | 2006-09-29 | Glaxo Group Ltd | Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs |
DE19913692A1 (de) | 1999-03-25 | 2000-09-28 | Basf Ag | Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen |
US6375963B1 (en) * | 1999-06-16 | 2002-04-23 | Michael A. Repka | Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof |
DE19929361A1 (de) | 1999-06-25 | 2001-01-04 | Basf Ag | Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen |
GB0008785D0 (en) * | 2000-04-10 | 2000-05-31 | Novartis Ag | Organic compounds |
DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
DE10046541A1 (de) * | 2000-09-19 | 2002-03-28 | Knoll Ag | Mechanisch stabile darreichungsformen, enthaltend Ubichinone |
US20050048112A1 (en) * | 2003-08-28 | 2005-03-03 | Jorg Breitenbach | Solid pharmaceutical dosage form |
WO2005035951A1 (en) * | 2003-10-08 | 2005-04-21 | The Lubrizol Corporation | System containing oxygen enriched diesel particulate filter and method thereof |
US20050096365A1 (en) * | 2003-11-03 | 2005-05-05 | David Fikstad | Pharmaceutical compositions with synchronized solubilizer release |
FR2861992B1 (fr) * | 2003-11-10 | 2007-07-20 | Sanofi Synthelabo | Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide. |
JP2007515458A (ja) * | 2003-12-23 | 2007-06-14 | テイボテク・フアーマシユーチカルズ・リミテツド | Hivプロテアーゼ阻害剤の自己ミクロ乳化性薬剤送達システム |
FR2866192B1 (fr) * | 2004-02-11 | 2006-04-28 | Johnson Controls Tech Co | Systeme et procede automatiques de reparation d'une carte electronique |
US7790190B2 (en) | 2004-03-20 | 2010-09-07 | Yasoo Health, Inc. | Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid |
US7318503B2 (en) | 2004-04-26 | 2008-01-15 | Akebono Corporation (North America) | Pad retaining clips |
EP2229945A1 (en) * | 2004-05-21 | 2010-09-22 | Japan Tobacco, Inc. | Combinations comprising a 4-isoquinolone derivative and anti-HIV agents |
EP1827416A1 (en) * | 2004-12-03 | 2007-09-05 | Abbott Laboratories | Pharmaceutical compositions |
-
2006
- 2006-07-19 EP EP06015076A patent/EP1880715A1/en not_active Withdrawn
-
2007
- 2007-07-17 US US12/305,870 patent/US9078921B2/en not_active Expired - Fee Related
- 2007-07-17 HU HUE07787658A patent/HUE032551T2/en unknown
- 2007-07-17 RS RS20170203A patent/RS55705B1/sr unknown
- 2007-07-17 RU RU2009105479/15A patent/RU2469708C2/ru active
- 2007-07-17 KR KR1020087032146A patent/KR101424588B1/ko active IP Right Grant
- 2007-07-17 CN CN2007800268668A patent/CN101489537B/zh active Active
- 2007-07-17 DK DK07787658.9T patent/DK2046298T3/en active
- 2007-07-17 BR BRPI0715582-4A patent/BRPI0715582A2/pt not_active IP Right Cessation
- 2007-07-17 PT PT77876589T patent/PT2046298T/pt unknown
- 2007-07-17 AU AU2007275177A patent/AU2007275177B2/en not_active Ceased
- 2007-07-17 MX MX2009000048A patent/MX2009000048A/es active IP Right Grant
- 2007-07-17 EP EP07787658.9A patent/EP2046298B1/en active Active
- 2007-07-17 JP JP2009519974A patent/JP5244102B2/ja active Active
- 2007-07-17 SI SI200731895A patent/SI2046298T1/sl unknown
- 2007-07-17 ES ES07787658.9T patent/ES2612865T3/es active Active
- 2007-07-17 LT LTEP07787658.9T patent/LT2046298T/lt unknown
- 2007-07-17 WO PCT/EP2007/057392 patent/WO2008009689A1/en active Application Filing
- 2007-07-17 CN CN201210270063.XA patent/CN103055316B/zh active Active
- 2007-07-17 CA CA2658395A patent/CA2658395C/en not_active Expired - Fee Related
- 2007-07-17 PL PL07787658T patent/PL2046298T3/pl unknown
-
2009
- 2009-02-17 ZA ZA2009/01110A patent/ZA200901110B/en unknown
-
2015
- 2015-07-14 US US14/799,430 patent/US9616130B2/en not_active Expired - Fee Related
-
2017
- 2017-02-17 CY CY20171100221T patent/CY1118873T1/el unknown
- 2017-02-28 HR HRP20170325TT patent/HRP20170325T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20170325T1 (hr) | Farmaceutska doza koja sadrži farmaceutski prihvatljivu otapajuću smjesu | |
CA2271196C (en) | Pharmaceutical compositions of hiv protease inhibitors with improved oral bioavailability | |
ES2653762T3 (es) | Forma de dosificación farmacéutica sólida que comprende una dispersión sólida inhibidora de proteasa del VIH | |
HRP20151383T1 (hr) | Farmaceutski pripravci koji sadrže nilotinib ili njegovu sol | |
US20110312973A1 (en) | Solid compositions | |
KR960703589A (ko) | 사람 면역결핍 바이러스-프로테아제 억제제의 약제학적 조성물(Pharmaceutical composition of HIV-protease inhibitors) | |
CA2359945A1 (en) | Inhibitors of crystallization in a solid dispersion | |
HRP20231613T1 (hr) | Pripravci koji sadrže sredstvo za unošenje i njihova priprava | |
AR055734A1 (es) | Una formulacion solida de dosificacion farmaceutica | |
HRP20140097T1 (hr) | Farmaceutski sastav jakog hcv-inhibitora za oralnu primjenu | |
RU2011117274A (ru) | Фармацевтическая композиция для модифицированного высвобождения | |
HRP20141006T1 (hr) | Farmaceutski pripravci koji sadrže 2-okso-1-pirolidin derivate | |
US20110034489A1 (en) | Solid dosage forms of hiv protease inhibitors | |
EA024538B1 (ru) | Твердая фармацевтическая композиция, содержащая соединение с анти-вгс (hcv) активностью | |
CA2600023A1 (en) | Solvent system for enhancing the solubility of pharmaceutical agents | |
KR20100103824A (ko) | 약학적 조성물 | |
CN102985074A (zh) | 包含一种或多种抗逆转录病毒活性成分的药物剂型 | |
JP2018154596A (ja) | アジルサルタン含有固形医薬組成物 | |
JP6630343B2 (ja) | 抗酸化剤を含有する固形製剤 | |
HRP940198A2 (en) | Retarded-action microtablet made of beta-phenylpropiophenone derivatives | |
US20240075026A1 (en) | Solid Pharmaceutical Compositions for Treating HCV | |
SI2269591T1 (en) | Improved pharmaceutical formulations | |
KR20190091005A (ko) | 안지오텐신 수용체 길항제를 포함하는 고체상의 약제학적 조성물 | |
US20130190337A1 (en) | Solid dosage forms of hiv protease inhibitors | |
PE20030098A1 (es) | Capsulas elasticas blandas y composiciones de las mismas |